English
Spanishwelcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.
rareRelated
-
Preoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...
-
Kellogg Eye Center – Thyroid Eye Disease CenterAt the Thyroid Eye Disease Clinic at the...
-
Management of Graves’ Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
-
Graves’ and Thyroid Eye Disease Support Group MeetingThis event is hosted by Graves' Dise...
-
The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of G...Graves' orbitopathy (GO) is the main ext...
-
Meta-Analysis of Methylprednisolone Pulse Therapy for Graves’ OphthalmopathyA meta-analysis was performed to evaluat...
-
Early Diagnosis of Thyroid Eye Disease (TED)Early Symptoms TED can first present wi...
